The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The selection of 3- and 14-month-old mice was strategically based on clinical relevance and previous characterization of the LDLr−/− model.
“The selection of 3‐ and 14‐month‐old mice was strategically based on clinical relevance (Zambón et al. 2010) and our previous characterization of the LDLr−/− model (Moreira et al. 2012; de Oliveira, Engel, de Paula, Melo, et al. 2020; Rodrigues et al. 2024).”
From LDL Cholesterol Modulates Astrocyte Metabolism, Lipid Handling, and Morphology: Evidence From In Vitro and In Vivo Models (2026) · cites this paper as Zambón et al. 2010
Patients with familial hypercholesterolaemia show a particularly high incidence of mild cognitive impairment.
“Patients with familial hypercholesterolaemia (FH) show a particularly high incidence of mild cognitive impairment (MCI), a prodromal stage of abnormal cognitive performance which precedes AD [2], [4].”
From ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage (2011) · cites this paper as [4]
The proportion of patients with FH showing abnormal cognitive function and meeting the criteria for MCI is significantly higher than in controls.
“These results are in line with those of epidemiological studies showing that the proportion of patients with FH showing abnormal cognitive function and meeting the criteria for MCI is significantly higher than in controls [4].”
From ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage (2011) · cites this paper as [4]
Hypercholesterolaemia may be an early risk factor for AD.
“Patients with FH are exposed to higher cholesterol levels from birth, and it is reported that hypercholesterolaemia may be an early risk factor for AD [2], [4].”
From ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage (2011) · cites this paper as [4]
Patients with FH are exposed to higher cholesterol levels from birth.
“Patients with FH are exposed to higher cholesterol levels from birth, and it is reported that hypercholesterolaemia may be an early risk factor for AD [2], [4].”
From ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage (2011) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Civeira, F. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.11.010 · Cited by 495
Self-citationKalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417
Clearance of amyloid β-peptide from brain: transport or metabolism?
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186
Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice
Cao, D., Fukuchi, K.-I., Wan, H., Kim, H., & Li, L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.011 · Cited by 106
Flagged first, then by citations
Research works printed but not linked: 28
- Masters, 2006, Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway, Brain, 129, 2823, 10.1093/brain/awl251 · DOI
- Glenner, 1984, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun, 120, 885, 10.1016/S0006-291X(84)80190-4 · DOI · Paper page
- Gandy, 2005, The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease, J Clin Invest, 115, 1121
- Pappolla, 2002, Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis, Free Radic Biol Med, 33, 173, 10.1016/S0891-5849(02)00841-9 · DOI
- Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol Dis, 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
- Refolo, 2001, A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease, Neurobiol Dis, 8, 890, 10.1006/nbdi.2001.0422 · DOI
- Simons, 1998, Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons, Proc Natl Acad Sci U S A, 95, 6460, 10.1073/pnas.95.11.6460 · DOI
- Sparks, 2000, Link between heart disease, cholesterol, and Alzheimer's disease: a review, Microsc Res Tech, 50, 287, 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L · DOI
- Pappolla, 2003, Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology, Neurology, 61, 199, 10.1212/01.WNL.0000070182.02537.84 · DOI · Paper page
- Kivipelto, 2006, Cholesterol as a risk factor for Alzheimer's disease—epidemiological evidence, Acta Neurol Scand Suppl, 185, 50, 10.1111/j.1600-0404.2006.00685.x · DOI · Paper page
- Notkola, 1998, Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease, Neuroepidemiology, 17, 14, 10.1159/000026149 · DOI
- Whitmer, 2005, Midlife cardiovascular risk factors and risk of dementia in late life, Neurology, 64, 277, 10.1212/01.WNL.0000149519.47454.F2 · DOI · Paper page
- Kivipelto, 2002, Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease, Ann Intern Med, 137, 149, 10.7326/0003-4819-137-3-200208060-00006 · DOI
- Arvanitakis, 2008, Statins, incident Alzheimer disease, change in cognitive function, and neuropathology, Neurology, 70, 1795, 10.1212/01.wnl.0000288181.00826.63 · DOI
- Newschaffer, 1992, Aging and total cholesterol levels: cohort, period, and survivorship effects, Am J Epidemiol, 136, 23, 10.1093/oxfordjournals.aje.a116417 · DOI
- Damgaard, 2005, The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population, Atherosclerosis, 180, 155, 10.1016/j.atherosclerosis.2004.12.001 · DOI
- Junyent, 2005, The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias, Arterioscler Thromb Vasc Biol, 25, 2203, 10.1161/01.ATV.0000183888.48105.d1 · DOI
- Pocovi, 2004, Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects, Semin Vasc Med, 4, 67, 10.1055/s-2004-822988 · DOI
- Yamamoto, 1984, The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA, Cell, 39, 27, 10.1016/0092-8674(84)90188-0 · DOI · Paper page
- Hamilton, 1967, Development of a rating scale for primary depressive illness, Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x · DOI
- Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
- Wenham, 1991, Apolipoprotein E genotyping by one-stage PCR, Lancet, 337, 1158, 10.1016/0140-6736(91)92823-K · DOI
- Gauthier, 2006, Mild cognitive impairment, Lancet, 367, 1262, 10.1016/S0140-6736(06)68542-5 · DOI
- Portet, 2006, Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure, J Neurol Neurosurg Psychiatry, 77, 714, 10.1136/jnnp.2005.085332 · DOI
- Canevari, 2007, Alzheimer's disease and cholesterol: the fat connection, Neurochem Res, 32, 739, 10.1007/s11064-006-9200-1 · DOI
- Solomon, 2007, Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study, Neurology, 68, 751, 10.1212/01.wnl.0000256368.57375.b7 · DOI
- Stewart, 2007, Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study, Arch Neurol, 64, 103, 10.1001/archneur.64.1.103 · DOI
- Elias, 2000, The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort, Arch Neurol, 57, 808, 10.1001/archneur.57.6.808 · DOI · Paper page
Cited by
Sorted by citations
Cholesterol in brain disease: Sometimes determinant and frequently implicated
Martín, M. G., Pfrieger, F., & Dotti, C. G. (2014) · The EMBO Reports · doi:10.15252/embr.201439225 · Cited by 304
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
Impaired cholesterol metabolism, neurons, and neuropsychiatric disorders
Cheon, S. Y. (2023) · Experimental Neurobiology · doi:10.5607/en23010 · Cited by 67
Wang, S.-H., Huang, Y., Yuan, Y., Xia, W.-Q., Wang, P., & Huang, R. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-175 · Cited by 44
Ramírez, C., Sierra, S., Tercero, I., Vázquez, J. A., Pineda, A., Manrique, T., & Burgos, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022712 · Cited by 31
de Oliveira, J., Engel, D. F., de Paula, G. C., Melo, H. M., Lopes, S. C., Ribeiro, C. T., Delanogare, E., Moreira, J. C. F., Gelain, D. P., Prediger, R. D., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190742 · Cited by 31
Baumart, G. J., Rodrigues, M. S., Sholl, J. N., de Sousa, A. C., Weber, A. F., Costa‐Beber, L. C., Farias, H. R., Costa, M. V., Peres, A. M., de Camargo, P. R., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70403 · Cited by 2
de Oliveira, J., de Bem, A. F., & Moreira, E. L. G. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12309
Metadata
- Authors
- Zambón, D., Quintana, M., Mata, P., Alonso, R., Benavent, J., Cruz-Sánchez, F., Gich, J., Pocoví, M., Civeira, F., Capurro, S., Bachman, D., Sambamurti, K., Nicholas, J., & Pappolla, M. A.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 123
- Issue
- 3
- Pages
- 267-274
- ISSN
- 0002-9343
- PMC
- PMC2844655
- Cited by
- 125
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
